---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-071704"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:42:12.422992+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Longeveron reports Q3 2022 net loss of $5.2M; completes Phase 2a Alzheimer's enrollment

## Summary
- Net loss of $5.2M ($0.25 per share) vs $4.9M in Q3 2021; revenue up to $0.3M from $0.2M.
- Completed enrollment in Phase 2a Lomecel-B trial for mild Alzheimer's Disease; topline results expected 2024.
- FDA granted Fast Track Designation for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS).
- Cash and short-term investments of $22.3M; expected runway into first half 2024.
- R&D expenses increased 45% to $2.9M; G&A decreased 31% to $2.1M.

## SEC filing metadata
- accession: 0001213900-22-071704
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/0001213900-22-071704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/ea168423-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-071704
- JSON: https://secwatch.observer/filing/0001213900-22-071704.json
- Plain text: https://secwatch.observer/filing/0001213900-22-071704.txt

## Key facts
- Earnings Releases
  Longeveron Inc. reported third quarter ended September 30, 2022 results: revenue $0.3 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $0.3 million
  - Result: reported results
  source text: Revenue for the third quarters of 2022 and 2021 was $0.3 million and $0.2 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1721484/000121390022071704/0001213900-22-071704-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.